{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:03:39Z","timestamp":1793833419395,"version":"4.6.1"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in hematologic malignancies, but its efficacy in solid tumors remains limited, primarily due to the immunosuppressive tumor microenvironment (TME) that hinders CAR-T cell trafficking and function. NKG2D CAR-T cells, which target stress-induced NKG2D ligands (NKG2DLs) broadly expressed on tumor cells, have shown promising potential in overcoming the immunosuppressive barriers of the solid TME. This review highlights recent advances in NKG2D CAR-T cell strategies for solid tumors, including innovations in CAR architecture, signaling pathway engineering, combination immunotherapy, and the development of armored CAR constructs. We further discuss the therapeutic potential, current challenges, and future directions of these approaches to inform the design of more effective and durable CAR-T cell therapies for solid tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1763843","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:37:10Z","timestamp":1770795430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Chen","family":"Liu","sequence":"first","affiliation":[{"name":"Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Stomatology, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of General Practice, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Qin","sequence":"additional","affiliation":[{"name":"Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Gansu Tumor Immunology Basic Disciplines Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Ye","sequence":"additional","affiliation":[{"name":"Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Gansu Tumor Immunology Basic Disciplines Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ren","sequence":"additional","affiliation":[{"name":"Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Gansu Tumor Immunology Basic Disciplines Research Center, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/bs9.0000000000000173","article-title":"CAR-T cell therapy: Where are we now, and where are we heading","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e22900","DOI":"10.1002\/jbt.22900","article-title":"The current knowledge concerning solid cancer and therapy","volume":"35","author":"Najafi","year":"2021","journal-title":"J Biochem Mol Toxicol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cells10061420","article-title":"NKG2D natural killer cell receptor-A short description and potential clinical applications","volume":"10","author":"Siemaszko","year":"2021","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17545","DOI":"10.3390\/ijms242417545","article-title":"The role of NKG2D and its ligands in autoimmune diseases: new targets for immunotherapy","volume":"24","author":"Wei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1580693","article-title":"The NKG2D axis: an emerging target in cancer immunotherapy","volume":"23","author":"Lazarova","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00661","article-title":"NKG2D\/NKG2-ligand pathway offers new opportunities in cancer treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/biology12081079","article-title":"The role and regulation of the NKG2D\/NKG2D ligand system in cancer","volume":"12","author":"Tan","year":"2023","journal-title":"Biol (Basel)"},{"key":"B14","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.20892\/j.issn.2095-3941.2018.0253","article-title":"The PI3K\/Akt\/GSK-3\u03b2\/ROS\/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility","volume":"16","author":"Jin","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \u201cOne for all, all for one","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12026-007-0060-9","article-title":"The NKG2D receptor: immunobiology and clinical implications","volume":"40","author":"Burgess","year":"2008","journal-title":"Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557644","article-title":"Designs of NKG2D-based immunotherapeutics for cancer","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2021.62.4.288","article-title":"Clinical impact of natural killer group 2D receptor expression and that of its ligand in ovarian carcinomas: A retrospective study","volume":"62","author":"Lee","year":"2021","journal-title":"Yonsei Med J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0585-3","article-title":"Clinical significance of the NKG2D ligands, MICA\/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis","volume":"58","author":"Li","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-957","article-title":"MICA\/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer","volume":"14","author":"Cho","year":"2014","journal-title":"BMC Cancer"},{"key":"B22","article-title":"Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity","volume":"62","author":"Pende","year":"2002","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21510","article-title":"Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients","volume":"118","author":"Watson","year":"2006","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-0872","article-title":"MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells","volume":"11","author":"Germain","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.22034\/apjcp.2018.19.3.661","article-title":"Analysis of the expression of surface receptors on NK cells and NKG2D on immunocytes in peripheral blood of patients with nasopharyngeal carcinoma","volume":"19","author":"Xu","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/biom10020301","article-title":"Recent advances in molecular mechanisms of the NKG2D pathway in hepatocellular carcinoma","volume":"10","author":"Wang","year":"2020","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)01960-3","article-title":"MICA and MICB genes: can the enigma of their polymorphism be resolved","volume":"22","author":"Stephens","year":"2001","journal-title":"Trends Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.2.902","article-title":"Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein","volume":"171","author":"R\u00f6lle","year":"2003","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.07.007","article-title":"IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells","volume":"120","author":"Song","year":"2008","journal-title":"Immunol Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1078","article-title":"Two human ULBP\/RAET1 molecules with transmembrane regions are ligands for NKG2D","volume":"173","author":"Bacon","year":"2004","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(03)00714-9","article-title":"ULBP4 is a novel ligand for human NKG2D","volume":"305","author":"Chalupny","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-011320","article-title":"ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15","volume":"108","author":"Sutherland","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(01)00095-4","article-title":"ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor","volume":"14","author":"Cosman","year":"2001","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s10020-025-01264-9","article-title":"Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma","volume":"31","author":"Kumari","year":"2025","journal-title":"Mol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejmech.2016.01.053","article-title":"Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin\u2019s lymphoma cell models","volume":"111","author":"Camodeca","year":"2016","journal-title":"Eur J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-738","article-title":"Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction","volume":"14","author":"Peng","year":"2014","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00447","article-title":"NKG2D ligand shedding in response to stress: role of ADAM10","volume":"11","author":"Zingoni","year":"2020","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/or.2024.8796","article-title":"A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review)","volume":"52","author":"Huang","year":"2024","journal-title":"Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-\u03b2","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"725-33","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia; chimeric antigen receptor-modified T cells for acute lymphoid leukemia; chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The european medicines agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.11665\/j.issn.1000-5048.20211125001","article-title":"Development strategies and clinical research progress of universal CAR-T cell drugs","volume":"54","author":"Wang","year":"2023","journal-title":"J China Pharm Univ"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-4047","article-title":"Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer","volume":"67","author":"Barber","year":"2007","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41419-025-07905-5","article-title":"ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation","volume":"16","author":"Zhang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e13201","DOI":"10.1111\/sji.13201","article-title":"Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches","volume":"96","author":"Chitadze","year":"2022","journal-title":"Scand J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3171\/2014.9.Jns132253","article-title":"Stem cell signature in glioblastoma: therapeutic development for a moving target","volume":"122","author":"Nakano","year":"2015","journal-title":"J Neurosurg"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-1766","article-title":"NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma","volume":"24","author":"Weiss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2019-129998","article-title":"Next generation NKG2D-based CAR T-cells (CYAD-02): co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy","volume":"134","author":"Fontaine","year":"2019","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519777","article-title":"Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-018-2796-z","article-title":"Origin and initiation mechanisms of neuroblastoma","volume":"372","author":"Tsubota","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1316439","DOI":"10.1080\/2162402x.2017.1316439","article-title":"MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma","volume":"6","author":"Brandetti","year":"2017","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e008460","DOI":"10.1136\/jitc-2023-008460","article-title":"Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells","volume":"12","author":"Baugh","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"13156","DOI":"10.3390\/ijms241713156","article-title":"Targeting NKG2DL with bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins on triple-negative breast cancer","volume":"24","author":"Kaidun","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2023.0043","article-title":"Annihilation of non-small cell lung cancer by NKG2D CAR-T cells produced from T cells from peripheral blood of healthy donors","volume":"43","author":"Jiang","year":"2023","journal-title":"J Interferon Cytokine Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1509173","DOI":"10.1080\/2162402x.2018.1509173","article-title":"DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells","volume":"8","author":"Zhao","year":"2019","journal-title":"Oncoimmunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106443","article-title":"CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid Malignancies","volume":"26","author":"Trinh","year":"2023","journal-title":"iScience"},{"key":"B74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12885-023-11806-1","article-title":"Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12885-025-13780-2","article-title":"CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models","volume":"25","author":"Zhi","year":"2025","journal-title":"BMC Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3670-0","article-title":"Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment","volume":"82","author":"Tao","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002361","article-title":"Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B78","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20460","article-title":"Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro","volume":"9","author":"Zarei","year":"2023","journal-title":"Heliyon"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15828","article-title":"Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41389-021-00353-8","article-title":"Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway","volume":"10","author":"Gao","year":"2021","journal-title":"Oncogenesis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863346","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer exhibit different immunological microenvironments and different responses to immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115740","article-title":"Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment","volume":"168","author":"Zhou","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1498706","article-title":"Co-expression of IL-15\/IL-15Ra complex enhances NKG2D-CAR T cell-mediated anti-pancreatic cancer immunity by activating the JAK\/STAT5 signaling pathway","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107952","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e23564","DOI":"10.4161\/onci.23564","article-title":"Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors","volume":"2","author":"Spear","year":"2013","journal-title":"Oncoimmunology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369406","article-title":"shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.7150\/thno.100555","article-title":"Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management","volume":"14","author":"Hansen","year":"2024","journal-title":"Theranostics"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24213","article-title":"Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment","volume":"81","author":"Sun","year":"2021","journal-title":"Prostate"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00884","article-title":"Past, current, and future of immunotherapies for prostate cancer","volume":"9","author":"Boettcher","year":"2019","journal-title":"Front Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e108925","DOI":"10.1371\/journal.pone.0108925","article-title":"Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion","volume":"9","author":"Lundholm","year":"2014","journal-title":"PloS One"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107619","article-title":"The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells","volume":"212","author":"Sui","year":"2025","journal-title":"Pharmacol Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/or_00001026","article-title":"Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA\/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity","volume":"24","author":"Yamanegi","year":"2010","journal-title":"Oncol Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462076","article-title":"A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma","volume":"15","author":"Hui","year":"2024","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000413","article-title":"Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non\u2013gene-edited allogeneic CAR T-cell therapy","volume":"45","author":"Michaux","year":"2022","journal-title":"J Immunother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2294-1","article-title":"NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib","volume":"106","author":"Hara","year":"2017","journal-title":"Int J Hematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101827","article-title":"Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells","volume":"5","author":"Obajdin","year":"2024","journal-title":"Cell Rep Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J Cell Physiol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2118210","article-title":"CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy","volume":"11","author":"Li","year":"2022","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112260","article-title":"Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview","volume":"194","author":"Mondal","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1042\/cbi20100431","article-title":"MMP9 mediates MICA shedding in human osteosarcomas","volume":"35","author":"Sun","year":"2011","journal-title":"Cell Biol Int"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1197-x","article-title":"Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility","volume":"51","author":"Shiraishi","year":"2016","journal-title":"J Gastroenterol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2013.8","article-title":"The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders","volume":"16","author":"Waldmann","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14653240510018037","article-title":"IL-15: targeting CD8+ T cells for immunotherapy","volume":"7","author":"Diab","year":"2005","journal-title":"Cytotherapy"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.92","article-title":"Immunotherapeutic applications of IL-15","volume":"4","author":"Croce","year":"2012","journal-title":"Immunotherapy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155258","article-title":"Interleukin-15 in autoimmunity","volume":"136","author":"Allard-Chamard","year":"2020","journal-title":"Cytokine"},{"key":"B128","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","article-title":"Interleukin 15 as a promising candidate for tumor immunotherapy","volume":"22","author":"Jakobisiak","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107637","article-title":"Chimeric cytokine receptor TGF-\u03b2 RII\/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer","volume":"212","author":"Ren","year":"2025","journal-title":"Pharmacol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.03.009","article-title":"Mouse models for immuno-oncology","volume":"9","author":"Bosenberg","year":"2023","journal-title":"Trends Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","author":"Ng","year":"2021","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:24:01Z","timestamp":1771928641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":134,"alternative-id":["10.3389\/fimmu.2026.1763843"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1763843","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1763843"}}